Skip to main content
Clinical Trials/NL-OMON46831
NL-OMON46831
Withdrawn
Not Applicable

Qualification of imaging methods to assess cancer drug induced interstitial lung disease (ImageILD) - EORTC-1658-IG

European Organisation for Research in Treatment of Cancer (EORTC)0 sites5 target enrollmentTBD
ConditionsDIILD10006436

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
DIILD
Sponsor
European Organisation for Research in Treatment of Cancer (EORTC)
Enrollment
5
Status
Withdrawn
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Sponsor
European Organisation for Research in Treatment of Cancer (EORTC)

Eligibility Criteria

Inclusion Criteria

  • \* Age \* 18 years
  • \* WHO performance status 0\-2
  • \* Life expectancy \> 6 months
  • \* Proven cancer diagnosis in a patient actively undergoing systemic anticancer
  • \* New onset symptoms (e.g. cough, fever, dyspnoea, and hypoxia) at any
  • time during or within 4 weeks of the last dose of anti\-cancer treatment
  • \* New onset radiological (CXR or CT) abnormalities within the lungs at any
  • time during or within 4 weeks of the last dose of anti\-cancer treatment
  • (e.g. diffuse lung changes, infiltrative opacification in the periphery of the
  • lung or ground glass changes) with a locally reviewed diagnosis of DIILD as

Exclusion Criteria

  • \* Primary lung tumor greater than 3cm
  • \* Lung metastatic lesion \> 2cm or greater than 5 metastases
  • \* Claustrophobia, or inability to undergo non\-contrast CT examination
  • \* Known or suspected non\-drug related ILD (e.g. lung abnormalities due to
  • other causes such as occupational exposure)
  • \* Previous thoracic lobectomy
  • \* Clinical, radiological or microbiological evidence of active lower respiratory
  • tract infection
  • \* Currently active, clinically significant heart disease, such as uncontrolled
  • class 3 or 4 congestive heart failure defined by the New York Heart

Outcomes

Primary Outcomes

Not specified

Similar Trials